Radiation Oncology Market Size, Share, Growth, and Industry Analysis, By Type (External Beam Radiation Therapy (EBRT),Brachytherapy), By Application (Blood Cancer (Leukaemia),Breast Cancer,Gastrointestinal Cancer,Respiratory/Lung Cancer,Skin Cancer), Regional Insights and Forecast to 2035

Radiation Oncology Market Overview

The global Radiation Oncology Market is forecast to expand from USD 6943.8 million in 2026 to USD 8179.1 million in 2027, and is expected to reach USD 30302.04 million by 2035, growing at a CAGR of 17.79% over the forecast period.

The Radiation Oncology Market has seen rapid clinical adoption, with over 60% of all cancer patients globally receiving some form of radiation therapy. By 2024, more than 17,000 linear accelerators were installed worldwide, with External Beam Radiation Therapy (EBRT) accounting for 72% of clinical procedures. Advanced modalities such as proton therapy are gaining ground, with installations increasing by 15% annually between 2022–2024. Hospitals dominate treatment delivery, with over 68% share, while specialty cancer centers represent 22%. Increased survival rates of 45–50% across various cancers underscore its importance in cancer care.

In the USA, more than 1.9 million new cancer cases were reported in 2023, and radiation therapy was used in 64% of treatments. The country operates over 3,300 linear accelerators, representing 25% of the global installed base. Brachytherapy accounts for 18% of treatments in gynecological and prostate cancers. Proton therapy centers grew from 41 in 2020 to 53 in 2024, indicating a 29% rise. The USA maintains leadership in technological advancements, with over 40% of R&D patents in radiation oncology registered by American institutions.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Over 68% of cancer patients require radiation therapy, with 72% preference for EBRT techniques.
• Major Market Restraint: High equipment costs restrict adoption, with 48% of hospitals in low-income nations unable to install new systems.
• Emerging Trends: AI and imaging integration increased by 32% between 2021–2024, enhancing treatment accuracy by 27%.
• Regional Leadership: North America accounts for 38% share, while Asia-Pacific follows with 29%.
• Competitive Landscape: Two players, Varian and Elekta, hold over 52% market share combined.
• Market Segmentation: EBRT leads with 72% share, while brachytherapy accounts for 28%.
• Recent Development: Between 2023–2025, over 19 new proton therapy centers were launched globally, increasing patient access by 22%.

Radiation Oncology Market Latest Trends

The Radiation Oncology Market has seen notable transformations with the adoption of precision oncology. By 2025, 72% of hospitals worldwide had adopted image-guided radiation therapy (IGRT) and intensity-modulated radiation therapy (IMRT). Proton beam therapy, previously limited, expanded its patient access by 22% between 2020–2024. Adaptive radiation therapy solutions, using AI-driven algorithms, were deployed in 31% of new centers in 2024, improving target accuracy by 27%.

Another significant trend is the growing demand for brachytherapy, with utilization in prostate cancer cases rising by 14% globally. In addition, hypofractionated radiation schedules have gained adoption, with 37% of lung cancer patients undergoing shorter, high-dose treatments.

Radiation Oncology Market Dynamics

DRIVER

"Rising cancer incidence and demand for advanced therapies"

With 19.3 million new cancer cases globally in 2023, radiation oncology became vital for over 60% of patients. External beam therapies like IMRT and IGRT accounted for 72% of treatments due to higher precision. Proton therapy utilization rose by 15% annually across 2021–2024, with the USA and Japan accounting for 65% of proton installations. This high patient dependency and adoption of advanced techniques continue to fuel growth.

RESTRAINT

"Limited access and high infrastructure costs"

Despite technological progress, 48% of hospitals in lower-income regions lack access to linear accelerators. Installation costs remain high, with advanced proton therapy centers requiring specialized facilities, restricting accessibility. Rural and semi-urban areas still face treatment gaps, with 32% of patients in Africa unable to access timely therapy. Furthermore, workforce shortages contribute to delays, with 27% fewer certified radiation oncologists in low-resource nations.

OPPORTUNITY

"Expansion in personalized and AI-based radiation oncology"

AI-enhanced platforms are reshaping treatment delivery, with 32% of global centers adopting machine learning for dose planning. Personalized cancer care adoption has expanded by 29% between 2021–2024. Real-time tumor tracking improved patient survival rates by 18%, particularly in lung and gastrointestinal cancers. Emerging markets in Asia-Pacific, where 21% new installations occurred in the last three years, present strong opportunities for investments in advanced treatment facilities.

CHALLENGE

"Rising costs and global disparities in care"

Radiation Oncology faces challenges in affordability, with over 50% of proton therapy costs exceeding standard radiation fivefold. Training remains a critical bottleneck, with 36% shortage in certified staff in developing countries. In addition, 26% of equipment in Latin America remains outdated beyond recommended service life. The disparities between high-income and low-income countries create unequal access, limiting the global impact of innovation.

Radiation Oncology Market Segmentation

The Radiation Oncology Market is segmented by type, including External Beam Radiation Therapy (72% share) and Brachytherapy (28% share). By application, it covers Breast Cancer (42%), Lung Cancer (21%), Gastrointestinal Cancer (18%), Blood Cancer (23%), and Skin Cancer (12%).

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

External Beam Radiation Therapy (EBRT): EBRT dominates with 72% market share, driven by advanced techniques such as IMRT, IGRT, and stereotactic body radiation therapy (SBRT). By 2024, 17,000 EBRT systems were operational globally. Among them, 32% feature adaptive therapy technologies. North America and Europe account for 67% of installations, while Asia-Pacific expanded capacity by 19% between 2022–2024.

The External Beam Radiation Therapy segment is estimated to reach USD 4223.41 million in 2025, holding 71.63% market share, and projected to grow at a CAGR of 18.12% due to advanced linear accelerator adoption.

Top 5 Major Dominant Countries in the EBRT Segment

• United States: EBRT market size at USD 1678.20 million in 2025, holding 39.73% share of global EBRT, growing at CAGR of 18.34%, supported by >350 radiation centers adopting proton therapy.
• Germany: EBRT valued at USD 453.80 million, accounting for 10.74% share, expanding at CAGR 17.92%, driven by >25 dedicated cancer treatment facilities.
• Japan: EBRT market at USD 399.50 million, contributing 9.46% share, with CAGR 17.88%, driven by >20 proton beam installations.
• China: EBRT valued at USD 635.80 million, making up 15.05% share, rising at CAGR 18.75%, backed by rapid expansion of >40 new cancer centers.
• United Kingdom: EBRT at USD 327.60 million, with 7.76% share, advancing at CAGR 17.54%, supported by >30 NHS-linked radiotherapy sites.

Brachytherapy: Brachytherapy accounts for 28% market share, particularly in gynecological and prostate cancers. Over 400,000 patients annually undergo brachytherapy procedures. Usage in cervical cancer cases accounts for 41% of applications in developing countries. Between 2021–2024, adoption rose by 14% due to minimally invasive techniques and better safety. Europe holds the highest share at 36%, followed by North America at 28%.

The Radiation Oncology market for Blood Cancer is expected to reach USD 883.20 million in 2025, representing 14.98% share, with growth at CAGR 16.95%.

Top 5 Major Dominant Countries in Blood Cancer Application

• United States: Market size USD 326.70 million, share 37.00%, CAGR 17.25%, with >60 leukemia-dedicated treatment centers.
• Germany: USD 102.50 million, share 11.60%, CAGR 16.83%, supported by >15 high-volume hospitals.
• China: USD 140.20 million, share 15.87%, CAGR 17.14%, led by >30 new blood cancer units.
• Japan: USD 96.40 million, share 10.91%, CAGR 16.74%, driven by >12 advanced radiotherapy centers.
• India: USD 82.70 million, share 9.36%, CAGR 16.45%, supported by >20 leukemia research facilities.

BY APPLICATION

Blood Cancer (Leukaemia): Radiation oncology is applied in 23% of leukemia cases, particularly in bone marrow transplant preparation. Pediatric leukemia cases represent 18% of radiation applications, with total body irradiation improving survival rates by 21% in transplant patients.

The Radiation Oncology market for Blood Cancer is expected to reach USD 883.20 million in 2025, representing 14.98% share, with growth at CAGR 16.95%.

Top 5 Major Dominant Countries in Blood Cancer Application

• United States: Market size USD 326.70 million, share 37.00%, CAGR 17.25%, with >60 leukemia-dedicated treatment centers.
• Germany: USD 102.50 million, share 11.60%, CAGR 16.83%, supported by >15 high-volume hospitals.
• China: USD 140.20 million, share 15.87%, CAGR 17.14%, led by >30 new blood cancer units.
• Japan: USD 96.40 million, share 10.91%, CAGR 16.74%, driven by >12 advanced radiotherapy centers.
• India: USD 82.70 million, share 9.36%, CAGR 16.45%, supported by >20 leukemia research facilities.

Breast Cancer: Breast cancer accounts for the largest application, with 42% of female cancer patients receiving radiation therapy. Hypofractionated schedules expanded by 33% between 2020–2024, while image-guided therapies improved tumor control by 28% in early-stage patients.

The Breast Cancer application segment is projected at USD 1576.70 million in 2025, capturing 26.74% share, with a robust CAGR of 18.15%.

Top 5 Major Dominant Countries in Breast Cancer Application

• United States: USD 615.40 million, 39.03% share, CAGR 18.45%, driven by >65% adoption of image-guided radiation therapy.
• China: USD 271.90 million, share 17.25%, CAGR 18.24%, supported by >80 urban cancer centers.
• Germany: USD 157.40 million, share 9.98%, CAGR 17.91%, with >25 oncology hospitals adopting adaptive radiation systems.
• Japan: USD 142.60 million, share 9.04%, CAGR 17.76%, driven by >40% radiotherapy adoption in early-stage breast cancer.
• United Kingdom: USD 129.30 million, share 8.20%, CAGR 17.68%, supported by >15 NHS-linked radiation oncology networks.

Gastrointestinal Cancer: Gastrointestinal cancers form 18% of radiation therapy cases globally, with rectal cancer treatments making up 46% of this segment. Radiation oncology improved local control by 24%, reducing recurrence rates in advanced-stage GI cancers.

The Gastrointestinal Cancer segment is projected at USD 1120.70 million in 2025, with 19.01% share, growing at CAGR 17.54%.

Top 5 Major Dominant Countries in Gastrointestinal Cancer Application

• United States: USD 437.90 million, share 39.07%, CAGR 17.95%, with >200 GI-focused radiation therapy centers.
• China: USD 184.30 million, share 16.44%, CAGR 17.61%, fueled by increasing colorectal cases.
• India: USD 115.70 million, share 10.32%, CAGR 17.28%, supported by >40 oncology research hubs.
• Germany: USD 102.80 million, share 9.17%, CAGR 17.21%, driven by hospital-based radiotherapy adoption.
• Japan: USD 95.20 million, share 8.49%, CAGR 17.05%, supported by >25 hospitals with advanced GI cancer units.

Respiratory/Lung Cancer: Lung cancer represents 21% of total applications, with stereotactic body radiation therapy (SBRT) increasing by 29% since 2020. Among early-stage cases, 47% of patients now undergo SBRT, achieving local control rates above 80%.

The Radiation Oncology market for Lung Cancer is valued at USD 1592.20 million in 2025, contributing 27.00% share, advancing at CAGR 18.45%.

Top 5 Major Dominant Countries in Lung Cancer Application

• United States: USD 624.50 million, share 39.22%, CAGR 18.72%, with >250 lung-focused radiation programs.
• China: USD 279.70 million, share 17.57%, CAGR 18.55%, driven by >50% smokers’ risk-based treatment.
• Japan: USD 148.10 million, share 9.30%, CAGR 18.22%, backed by >20 cancer centers.
• Germany: USD 144.80 million, share 9.09%, CAGR 18.11%, supported by specialized thoracic oncology hospitals.
• United Kingdom: USD 126.50 million, share 7.95%, CAGR 18.04%, with >18 leading lung oncology clinics.

Skin Cancer: Skin cancer accounts for 12% of radiation oncology applications, mostly in elderly patients. Non-melanoma cases dominate, with 25% growth in radiation adoption between 2021–2024 due to non-surgical treatment demand in high-risk groups.

The Skin Cancer application is valued at USD 722.30 million in 2025, holding 12.23% share, advancing at CAGR 16.89%.

Top 5 Major Dominant Countries in Skin Cancer Application

• United States: USD 278.40 million, share 38.55%, CAGR 17.05%, with >70% adoption of superficial radiation therapy.
• Germany: USD 95.80 million, share 13.26%, CAGR 16.84%, backed by >20 dermatology hospitals.
• Australia: USD 91.20 million, share 12.63%, CAGR 16.79%, given high UV-related skin cancer rates.
• China: USD 86.10 million, share 11.91%, CAGR 16.95%, with >12 regional skin cancer centers.
• United Kingdom: USD 79.40 million, share 10.99%, CAGR 16.82%, supported by NHS oncology programs.

Radiation Oncology Market Regional Outlook

Radiation oncology procedures are distributed with 38% share in North America, 29% in Asia-Pacific, 24% in Europe, and 9% in Middle East & Africa.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America leads with 38% global market share, fueled by advanced infrastructure. The USA alone accounts for 25% of global linear accelerators. Proton therapy centers rose from 41 in 2020 to 53 in 2024, marking a 29% increase. Canada expanded brachytherapy access, treating 14% more patients annually since 2021. Radiation oncology is supported by federal initiatives, with over 35% of oncology R&D funding directed to radiation technologies.

The North America Radiation Oncology Market is projected at USD 2198.70 million in 2025, contributing 37.29% share, with a growth rate of CAGR 18.12% driven by strong U.S. dominance and advanced cancer care facilities.

North America - Major Dominant Countries in the Radiation Oncology Market

• United States: USD 1820.40 million, share 82.79%, CAGR 18.34%, with >500 dedicated radiation oncology centers.
• Canada: USD 212.80 million, share 9.67%, CAGR 17.88%, driven by >25 specialized cancer institutes.
• Mexico: USD 95.50 million, share 4.34%, CAGR 17.65%, supported by rapid expansion of >10 radiation centers.
• Cuba: USD 38.40 million, share 1.75%, CAGR 17.12%, with government-driven oncology initiatives.
• Brazil (cross-regional in Americas): USD 31.60 million, share 1.44%, CAGR 16.95%, supported by advanced treatment adoption.

EUROPE

Europe represents 24% market share, with Germany, France, and the UK accounting for 61% of installations. Collaborative networks improved access, with 42% of hospitals part of EU-wide cancer care projects. Adoption of IGRT increased by 27% between 2021–2024, especially in breast cancer treatments. Eastern Europe, however, lags, with 31% fewer installations per capita compared to Western Europe.

The Europe market is estimated at USD 1762.40 million in 2025, contributing 29.89% share, with expansion at CAGR 17.56%, supported by Germany, France, and the UK leading technological advancements.

Europe - Major Dominant Countries in the Radiation Oncology Market

• Germany: USD 498.60 million, share 28.30%, CAGR 17.92%, supported by >25 specialized oncology hospitals.
• France: USD 372.10 million, share 21.12%, CAGR 17.65%, led by >20 major cancer centers.
• United Kingdom: USD 342.50 million, share 19.43%, CAGR 17.54%, driven by NHS expansion in radiotherapy.
• Italy: USD 278.90 million, share 15.83%, CAGR 17.41%, supported by >18 hospitals adopting EBRT.
• Spain: USD 270.30 million, share 15.32%, CAGR 17.34%, with >15 public-private oncology partnerships.

ASIA-PACIFIC

Asia-Pacific holds 29% share, driven by China, Japan, and India. China has over 3,000 radiotherapy units, representing 18% of global installations. India expanded capacity by 21% in the last three years, adding over 200 new machines. Japan dominates proton therapy with 23 active centers, accounting for 18% of the global total. The region has seen a 32% rise in hypofractionated treatments between 2021–2024.

Asia Radiation Oncology Market size is USD 1531.20 million in 2025, holding 25.96% share, growing at CAGR 18.29%, led by China, Japan, and India driving oncology technology adoption.

Asia - Major Dominant Countries in the Radiation Oncology Market

• China: USD 795.20 million, share 51.92%, CAGR 18.75%, with >40 oncology centers.
• Japan: USD 410.60 million, share 26.82%, CAGR 17.88%, supported by high-tech treatment adoption.
• India: USD 228.90 million, share 14.95%, CAGR 17.67%, driven by >70 oncology hospitals.
• South Korea: USD 65.40 million, share 4.27%, CAGR 17.54%, supported by advanced radiotherapy systems.
• Singapore: USD 31.10 million, share 2.03%, CAGR 17.28%, driven by specialized cancer hubs.

MIDDLE EAST & AFRICA

MEA accounts for 9% share, with South Africa, UAE, and Saudi Arabia leading adoption. Over 70% of Africa still lacks access, with 26% of existing systems outdated. The Middle East expanded installations by 19% between 2021–2024, particularly in UAE cancer centers. Training remains a key gap, with 35% fewer oncologists per capita compared to global standards.

The MEA Radiation Oncology Market is forecasted at USD 402.70 million in 2025, holding 6.83% share, advancing at CAGR 16.95%, supported by growing investments in oncology care infrastructure.

Middle East and Africa - Major Dominant Countries in the Radiation Oncology Market

• Saudi Arabia: USD 115.40 million, share 28.65%, CAGR 17.34%, supported by >10 major oncology hospitals.
• UAE: USD 92.30 million, share 22.91%, CAGR 17.25%, boosted by >8 dedicated cancer centers.
• South Africa: USD 77.20 million, share 19.17%, CAGR 16.87%, led by >12 regional radiation oncology units.
• Egypt: USD 68.40 million, share 16.98%, CAGR 16.78%, with >10 cancer institutes.
• Israel: USD 49.40 million, share 12.27%, CAGR 16.65%, supported by leading hospitals with radiotherapy adoption.

List of Top Radiation Oncology Market Companies

• Elekta
• NTP Radioisotopes
• Varian Medical Systems
• IBA Worldwide
• Nordion
• Carl Zeiss Meditec
• iCAD
• Accuray
• IsoRay
• BD
• Mevion Medical Systems
• Canon Medical Systems

Top Two Companies with highest share

Varian Medical Systems: holding approximately 29% global market share, driven by its leadership in linear accelerators, proton therapy solutions, and AI-integrated treatment planning systems.

Elekta: accounting for about 23% market share, supported by its strong presence in MRI-Linac systems, brachytherapy solutions, and global hospital partnerships.

Investment Analysis and Opportunities

Investments in the Radiation Oncology Market are accelerating, with over 19 proton therapy centers added between 2023–2025. Venture capital funding increased by 28% year-on-year, particularly in AI-enhanced radiotherapy planning platforms. Asia-Pacific accounted for 35% of new installations, with India alone adding 200 units in three years. Public-private partnerships represent 21% of funding models in Europe, expanding access.

Opportunities lie in expanding brachytherapy, with utilization growing 14% globally since 2021. Tele-oncology platforms, enabling remote planning, increased adoption by 34% in 2023.

New Product Development

Innovation drives the Radiation Oncology Market. Between 2023–2025, AI-integrated treatment planning systems rose by 32%, enabling real-time adjustments. Mevion developed compact proton therapy units, reducing space by 40%. Elekta and Varian introduced adaptive radiotherapy, used in 31% of new centers in 2024.

Brachytherapy innovations include MRI-guided applicators, improving precision by 27%. Portable linear accelerators, under development, aim to reduce installation costs by 22%. Imaging fusion technologies, combining PET and MRI, expanded in 28% of global cancer centers by 2024. Digital twins for oncology patients entered 15% of research hospitals, aiding personalized treatment.

Five Recent Developments

• Varian Medical Systems launched Halcyon adaptive therapy platform in 2023, adopted in 18% of U.S. centers.
• Elekta introduced MRI-Linac expansions in 2024, used by 26% of European hospitals.
• Mevion installed compact proton therapy units in 7 global centers by 2024.
• Accuray expanded CyberKnife usage, treating 11% more lung cancer patients in 2023–2024.
• IBA Worldwide partnered with Asian hospitals in 2025, delivering 5 new proton therapy installations.

Report Coverage of Radiation Oncology Market

The Radiation Oncology Market Report provides in-depth analysis of type, application, and regional dynamics. It covers EBRT with 72% global share and brachytherapy at 28%. Applications across breast cancer (42% share), lung cancer (21%), and GI cancers (18%) are thoroughly analyzed.

Regional insights highlight North America with 38% share, Europe with 24%, Asia-Pacific with 29%, and MEA with 9%. The report details competitive strategies, where Varian and Elekta dominate with 52% combined share.

Key findings include AI adoption at 32%, proton center expansion by 22%, and brachytherapy growth of 14%. The coverage extends to investment patterns, where Asia-Pacific accounted for 35% of new units in three years. Opportunities in tele-oncology, compact proton therapy, and adaptive solutions are emphasized.

Radiation Oncology Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 6943.8 Million in 2026
Market Size Value By	USD 30302.04 Million by 2035
Growth Rate	CAGR of 17.79% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : External Beam Radiation Therapy (EBRT) Brachytherapy By Application : Blood Cancer (Leukaemia) Breast Cancer Gastrointestinal Cancer Respiratory/Lung Cancer Skin Cancer
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample